KBC Securities NV is a securities and brokerage firm based in Brussels, Belgium, founded in 1991. The company specializes in providing a range of financing advisory services, including equity capital markets, mergers and acquisitions, syndication, and market making. KBC Securities also offers expertise in loan and debt markets, project finance, export finance, and both acquisition and leveraged finance. The firm is involved in initial public offerings, secondary public offerings, bonds, private placements, and fairness options. Its services cater to various sectors, notably biotechnology and communication technology, as well as information and research within the European equity market.
PanTera focuses on the large-scale production of actinium-225, a promising radioisotope for targeted cancer therapies. The company aims to improve accessibility to personalized nuclear medicine treatments while ensuring sustainability through the recycling of materials in their production process.
Ablynx
Post in 2014
Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These innovative proteins are designed to address a variety of serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. Currently, Ablynx has around 25 projects in its pipeline, with five Nanobodies in clinical development. By combining the advantages of traditional antibodies and small chemical molecules, Ablynx aims to provide new therapeutic options that can significantly improve patient care and outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.